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Background: The half of hyperalphalipoproteinemia (HALP) in Japan is caused by CETP gene mu-
tations. Other than two prevalent mutations (D442G and Intron 14 splicing donor site +1 G>A), 
some rare CETP mutations are found in Japanese HALP subjects. 
Methods: CETP gene analysis of genomic DNA from subjects was performed by restriction frag-
ment length polymorphism (RFLP) and sequencing analysis. Mutations which were suspected to 
cause a splicing defect or a protein secretion defect were investigated in COS-1 cells transfected 
with a CETP minigene construct or a cDNA expression vector.  
Results: Each of three subjects was identified as a carrier of CETP gene mutation of a compound 
heterozygote of c.653_654delGGinsAAAC and Intron 14 splicing donor site +1 G>A, a heterozy-
gote of c.658G>A or a homozygote of L261R. The c.658G>A mutation was located at the last nu-
cleotide of exon 7, and it was confirmed to cause splicing abnormality revealed by the CETP 
minigene analysis. The L261R CETP was not secreted to conditioned media of the cells. 
Conclusions: Three novel CETP gene mutations are responsible for HALP by CETP deficiency. It 
is predicted that there are more rare CETP gene mutations in Japanese, and these multiple rare mu-
tations alone or a combination with each of prevalent mutations responsible for mild-to-moderate 





Plasma CETP is a major modulator of high density lipoprotein cholesterol (HDL-C) concentration 
in human. CETP has the role of exchange neutral lipids between lipoproteins. CETP transfers cho-
lesterol ester (CE) from HDL to apolipoprotein B (apo B) containing lipoprotein such as chylomi-
cron or very low density lipoprotein (VLDL), and transfers triglyceride in an opposite direction. 
HDL-TG which transferred by CETP is hydrolyzed by hepatic lipase and HDL particle size reduces, 
thereby, it promotes the catabolic rate of apolipoprotein A-I in HDL [1].  
CETP is purified from human plasma as a 74 kDa glycoprotein [2]. It forms the boomerang 
shape and has a long tunnel with two openings, and phospholipids are plugging as sides of the tun-
nel openings and two of CE or TG bind in the tunnel [3]. The level of CETP activity varies in ani-
mal species, and mice, rats and dogs have almost no CETP activity because functional CETP gene 
is lost in their evolutionary process [4]. While rabbits and monkeys have high CETP activity, hu-
mans, hamsters and chickens have intermediate CETP activity [5]. 
CETP deficiency in human was firstly reported in Japanese hyperalphalipoproteinemia (HALP) 
[6]. Complete CETP deficiency presents extremely high HDL-cholesterol level and relatively low 
low density lipoprotein cholesterol (LDL-C) level [7]. About a half of HALP in Japan are caused 
by CETP gene mutations, and two prevalent mutations of D442G (allele frequency, 3.4% in Japa-
nese population) and intron 14 splice donor site +1 G>A (Int14+1A) (0.8%) are well characterized 
[8, 9]. The homozygote of D442G causes partial CETP deficiency by -54% and a moderate in-
crease in HDL-C (mean, 96 mg/dL), while the homozygote of Int14+1A causes complete CETP 
deficiency and extremely high level of HDL-C (mean, 167 mg/dL) [10].  
In the present study, we identified novel CETP mutations in marked HALP Japanese subjects, 
and we add more information on a heterogeneity of CETP gene mutations in Japanese.  
 
2. Materials and methods 
2.1. Subjects 
Two Japanese subjects with high HDL-C levels and undetectable CETP mass were investigated. 
The subject 1 was a 65 year-old female. She was aware of extremely high HDL-C level (224 mg/dl) 
at health check-up at her age of 46. Subject 1 had a history of hypertension and her brother is 
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HALP and had hypertension treated with amlodipine 5 mg daily since 61 years-old (146/100 
mmHg). He had a regular alcohol intake (50-75 g/day). Both subjects had mild carotid atheroscle-
rosis (IMT 0.9 mm), but they do not have atherosclerotic vascular disease. Subject 2 was a 50 year-
old female and she was HALP otherwise healthy. 
About 45 unrelated subjects from outpatients were referred to the lipid clinic of Kanazawa uni-
versity hospital or its affiliated hospitals in 1996-2009, and we choose cutoff value with serum 
CETP mass levels of <1.8 μg/ml and HDL-C levels of 60 mg/dl. The 41 individuals were excluded 
from the mutation screening because they had a D442G or Int14+1A mutation in CETP gene by 
PCR-based RFLP screening method (D442G heterozygotes: n=10, D442G homozygotes: n=3, 
Int14+1A heterozygotes: n=20, Int14+1A homozygotes: n=4, D442G/Int14+1A compound hetero-
zygotes: n=4). The 4 individuals were selected as candidates for further CETP gene mutation anal-
ysis. We identified a heterozygote of novel mutation in CETP gene in subject 3 by this analysis. 
Subject 3 was a 72 year-old female with manic depressive psychosis. She had both bladder and co-
lon cancer, and she received operations at her age of 55 and 70, respectively. Her HDL-C levels 
varied from 79 to 169 mg/dL in 5 year clinical record. None has died of cardiac cause in her family. 
All investigated subjects gave their informed consent. The study protocol was approved by the Eth-
ical Committee of Kanazawa University Graduate School of Medical Science. 
 
2.2. Biochemical analyses 
Blood samples were collected after a 12-h fast, unless otherwise noted. Serum TC and triglyceride 
(TG) were determined by enzymatic methods. Cholestest®N HDL (Sekisui Medical, Tokyo, Japan) 
was used for measurement of HDL-C, and Friedewald calculation was used for LDL-C estimation 
because a direct method for LDL-C has not been validated in CETP deficiency [7, 11]. Serum 
apolipoprotein concentrations were determined by immunoassay. CETP mass in serum was meas-
ured by enzyme immunoturbidimetry [12]. 
 
2.3. Genetic analyses 
Genomic DNA was prepared from peripheral white blood cells using a Genomic Purification Kit 
(Gentra Systems, Minneapolis, MN). The promoter region, 16 exons and intronic junctions of 
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CETP gene were amplified by PCR using specific primers. Specific primers were designed using 
Primer 3 plus online software (http://www.bioinformatics.nl/primer3plus.) [13]. Screening analysis 
was performed for two prevalent mutations of CETP gene, Int14+1A and D442G, using RFLP 
method as previously described [9]. PCR was performed under the following conditions: 95○C for 2 
min; 30 cycles of 95○C for 10 s; each optimized annealing temperature for 10 s; 72○C for 30 s. We 
select 55－60○C of annealing temperature on each primer. DNA direct sequencing was performed 
using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied biosystems, Foster City, CA) on the 
ABI PRISM 310 Genetic Analyzer (Applied biosystems). The purified PCR production of exon 7 
was ligated into pMD-20 vector (Takara Bio, Tokyo, Japan) by Mighty TA-cloning kit (Takara 
Bio) and then transformed to E. coli HST premium 08 (Takara Bio). Subclones were sequenced by 
ABI 3700 Genetic Analyzer. 
 
2.4. Construction of CETP minigene and cDNA plasmids 
To investigate effects of novel mutations for CETP gene splicing and expression, wild and mutant 
types of CETP minigene plasmid and cDNA plasmid were constructed. For a minigene plasmid, 
from exon 5 to 8 region of lambda CG5 CETP genomic clone [14] was amplified by PCR, and the 
product was digested by RsrII and SacII restriction enzymes. The pCU plasmid [15], in which ex-
ons and introns of 7-10 of CETP genomic region was replaced in the cDNA, was a kind gift from 
Dr. Alan Tall (Columbia University, NY, USA). The pCU was similarly digested by RsrII and Sac 
II, and PCR product which included CETP exon 5-8 was ligated to pCU plasmid. This plasmid 
was named to pCU5-11 and used as a wild type CETP minigene plasmid. Plasmid construct of 
CETP gene region was shown in Fig.4. For CETP cDNA expression vector, pCU plasmid and 
CETP cDNA region of pLAY WT [16] were digested by EcoRV, and they were ligated. L261R 
mutation in CETP cDNA expression plasmid was generated using PCR-based site-directed muta-
genesis. Mutations were confirmed by sequencing. Plasmid preparations were made using alkali 




2.5. Cell culture and transfections 
Monkey kidney COS-1 cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 
10 % fetal bovine serum (Invitrogen Corporation, Carlsbad, CA). Cells were split approximately 16 
h prior to transfection in 6-wells plate (2×105 cells per well). Transient expressions of plasmid 
DNA for cells were performed by the polyethylenimine (PEI) method [17]. The plasmid DNA was 
mixed with PEI and OptiMEM (Invitrogen) at nitrogen of PEI /phosphate of DNA ratio 11.5, and 
incubated for 30 min at room temperature. Cells were washed twice with PBS(-), and transfection 
solution was added. The cells were incubated for 8 h at 37○C, 5 % CO2. Then, the same volume of 
complete medium to transfection solution was added without removing the transfection solution, 
and cells were incubated for 48 h. From each plate, cells and medium were collected and stored at -
70○C for subsequent determination of CETP immunoreactive mass and mRNA.  
 
2.6. Analysis of CETP mass and RNA 
CETP mass in conditioned medium was determined by ELISA (Bio Medical Laboratories, Saitama, 
Japan). Total RNA from transfected cells was isolated by ISOGEN (WAKO Pure Chemicals, Osa-
ka, Japan). The reaction of reverse transcription was performed using RevertAid first strand cDNA 
synthesis kit (Thermo Fisher Scientific, Waltham MA) with 1 μg of total RNA according to the 
manufacturer's instructions. The cDNA was amplified using primers CETP E2A322 (5'-cag ata tca 
cgg gcg aga ag-3') and CETP E9B997 (5'-cga gtg gaa gac tcg ctc a-3'). PCR product was separated 
on 3 % NuSieve3:1agarose (Lonza, Basel, Switzerland) gel and semi-quantified analysis of RT-
PCR products amounts were performed by using Typhoon 9400 imaging analyzer (GE Healthcare 
UK, Little Chalfont, England). Sequences of RT-PCR products were confirmed with direct se-
quencing.  
 
2.7. Mutation nomenclature 
Mutations for changes at DNA levels are described according to CETP cDNA sequence Genbank 
ID: NT_000078. For cDNA numbering +1 corresponds to the A of the ATG translation initiation 
codon. Amino acid numbers are described according to CETP protein sequence PDB ID: 2OBD_A 
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as CETP mature protein.  
 
3. Results 
3.1. Clinical and biochemical characteristics of CETP gene mutation  
The pedigree of subject 1 is shown in Fig.1. The plasma lipid profile, CETP concentration and oth-
er parameters in the subject 1, her family members, subject 2 and subject 3 are shown in Table 1. 
Subject 1, her brother and subject 2 were the complete deficiency of CETP.  
Subject 1 and her brother had extremely high levels of HDL-C (subject 1: 223 mg/dL, II-4: 237 
mg/dL). Her daughter had high HDL-C level (III-1: 105 mg/dL), and her son had mild elevated 
HDL-C level (II-3: 63 mg/dL). Subjects 2 and 3 had high HDL-C levels (147 mg/dL and 162 
mg/dL, each). Although she had highly elevated HDL-C levels, subject 3 had partial CETP defi-
ciency and her plasma CETP mass was 1.1 μg/mL being a half of reference value. All probands had 
no clinical sign of cardiovascular disease.  
  
3.2. Analysis of CETP gene 
Subject 1, her brother and daughter were found to have the Int14+1A heterozygote by RFLP 
screening although subject 1 and her brother had complete CETP deficiency, so we further ana-
lyzed CETP genes of her family by sequencing method. As a result, they were found to be the 
compound heterozygotes for Int14+1A and a deletion of GG and an insertion of AAAC in 
c.653_654 sites (c.653_654delGGinsAAAC) in exon 7 (Fig.2). The c.653_654delGGinsAAAC mu-
tation is a novel mutation in CETP gene, and it is predicted to cause a frame shift leading to a 
premature stop codon in exon 8 (amino acid position 218). By sequencing, her daughter did not 
have any other mutation except Int14+1A, and her son was found to be the 
c.653_654delGGinsAAAC heterozygote (Fig.1).  
Subject 2 was the homozygote for substitution of nucleotide T to G at c.725 position. This substitu-
tion causes amino acid change at codon 261 from leucine (CTG) to arginine (CGG) (Fig.3). Subject 
3 was found to be the heterozygote of c.658G>A at the last nucleotide in exon 7 (Fig.2). She had 




3.3. The effect of c.658 G>A mutation for CETP pre-mRNA splicing 
The c.658G>A mutation identified in subject 3 is located at the last nucleotide of exon 7, which is 
likely to affect 5' splicing consensus sequence. Therefore, we examined its effect for CETP pre-
mRNA splicing. We constructed CETP wild type and c.658 G>A mutated minigene plasmid, and 
examined whether exon skipping is caused in mutated minigene construct transfected COS-1 cells. 
RT-PCR product of CETP cDNA region from wild type transfected cells had 688 bp length frag-
ment, while products from the c.658G>A plasmid transfected cells appeared as two bands, a minor 
band of 628 bp and a major band of 558 bp. As a result of sequencing analysis, fragment of 628 bp 
was skipping exon 7 (70 bp), and fragment of 558 bp skipped both exon 6 (60 bp) and 7 (Fig.4). 
The skipping of exon 7 or exon 6-7 is thought to cause frame shift leading a premature stop codon. 
Semi-quantification of RT-PCR product from the c.658 G>A plasmid transfected cells revealed rel-
ative amounts of exon 7 skipping transcripts and both exon 6 and 7 skipping transcripts were each 
32.0% and 68.0% in total product amounts from the c.658 G>A plasmid transfected cells (Fig.4).  
 
3.4. The influence of missense mutations for CETP secretion 
To assess the influences of L261R mutation for CETP secretion, we measured CETP protein mass 
in conditioned media from COS-1 cells transiently transfected with the wild type L261R mutant 
CETP. CETP mass in the medium of wild type was 54.4±21.2 ng/mL, while that from L261R was 
less than the detective limit (<0.25 ng/mL) (Table 2). The position of L261R was highly conserved 
in CETP genes of various species (Fig.5) 
 
4. Discussion 
In the present study, three novel CETP gene mutations (c.653_654delGGinsAAAC, c.658 G>A and 
L261R) were identified in Japanese HALP subjects. The c.653_654delGGinsAAAC mutation 
which was identified in subject 1 showed complete CETP deficiency as the compound heterozygote 
with Int14+1A mutation. The c.653_654delGGinsAAAC was predicted to cause frame shift leading 
to a premature stop codon. The truncated mRNA by the mutation is thought to be eliminated in 
nonsense-mediated mRNA decay system, and the mutated CETP protein would be hardly produced. 
The Int 14+1G>A mutation is also known to cause exon skipping leading to a premature stop co-
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don, and the amounts of its aberrant mRNA in cell are about 1/3 of that of wild type [18]. The ex-
tended 3' UTR length by the premature stop codon is longer, and the mRNA is more degraded [19]. 
Thus, the mRNA having c.653_654delGGinsAAAC mutation would be degraded more rapidly than 
that of Int14+1G>A. 
The c.658G>A mutation was identified as the heterozygote in subject 3 whose plasma CETP 
level was half as that of controls, and it located at the last nucleotide of exon 7 within 5' splicing 
donor consensus sequence. We showed this mutation caused two forms of exon skipping in COS-1 
cells, both of exon 6 and 7 skipping or only exon 7 skipping. The major transcripts skipped both of 
exon 6 and 7. The transcripts skipping exon 6 and 7 or only exon 7 both cause frame shift leading 
to a premature stop codon, and these aberrant mRNA would be degraded rapidly. Intron 7+1 G>T 
mutation, which was located at the next to c.658 position, which was identified in Caucasians, and 
the transcripts from peripheral leukocytes of the mutation carrier subject skipped only exon 7 [20]. 
The reason why patterns of exon skipping between Intron 7+1 G>T mutation and c.658G>A muta-
tion were different was unknown. However, we used overexpressed CETP minigene construct in 
COS-1 cells because RNA from subject 3 was not available, and distinct kinds of cells or differ-
ences between natural or overexpressed expression might account for a different exon skipping pat-
tern.  
We also thought the possibility that c.658G>A did not affect splicing and it caused amino acid 
substitution, A203T, so we constructed c.658G>A mutated CETP cDNA plasmid and performed 
CETP protein expression analysis. As the result, CETP protein mass in the medium and the tran-
scripts from transfected cell had not significantly changed compared to those of wild-type cell 
(supplemental fig.1), and it suggests that c.658G>A mutation caused abnormal splicing but it does 
not have a missense effect.  
Subject 3 had also I405V polymorphism as the heterozygote, but it was reported that the effect of 
I405V as 405VV homozygote for plasma CETP protein level by meta-analysis was –0.19 μg/mL 
less [21]. I405V polymorphism would decrease CETP mass in subject 3 slightly, but c.658G>A 
would cause CETP deficiency (1.1 μg/mL) by a single mutant allele causing a splicing defect. 
The L261R mutation was identified in subject 2 who resulted in the complete CETP deficiency, 
and it located in exon 9. CETP protein expression analysis showed CETP protein in the medium 
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from transfected cell was not detected. The transcript levels of L261R cell was not significantly 
changed compared to the wild type (supplemental fig.1), and L261R mutation is predicted to cause 
a secretion defect. The position of L261R is predicted to be located at surface of the neck region of 
the CETP tunnel. Y375S, F265R and F270R are CETP mutagenesis mutants which are not secreted, 
and these structural positions are located at surfaces in the neck region and they are in the vicinity 
of L261R position [3]. Probably, these surfaces of the neck region would be essential for CETP 
protein secretion.   
Subjects 1 and 2 were marked HALP with homozygotes of CETP mutation, but subjects with 
heterozygotes in this study had various HDL-C levels. Other than CETP, LIPC and LPL are re-
sponsible for elevated HDL-C level, and T allele of LIPC gene -514C/T polymorphism and 447X 
allele of LPL gene S447X polymorphism are well known to both cause 3 mg/dL of elevated HDL-
C levels in Japanese (LIPC -514T allele: 75%, LPL 447X allele: 22% in Japanese population) 
[22,23]. If subjects who have a heterozygote of CETP mutation but rather high levels of HDL-C, 
further analysis involving endothelial lipase [24] and scavenger receptor class B type I (SR-BI) 
[25,26] activities is needed. 
Many CETP gene mutations are reported, such as nonsense mutations (n=8), splice junction mu-
tations (n=6), missense mutations (n=5), small gene deletions and insertions (n=4), promoter muta-
tions (n=2) and others (n=1) (Fig.6) [8, 9, 20, 27-46]. In the present study, we identified 
c.653_654delGGinsAAAC and c.658G>A from several subjects with HALP, and it suggests that 
nonsense and splicing defect mutations account for the majority of CETP gene mutations.  
In summary, it is predicted that there are more rare CETP gene mutations in Japanese, and it 
suggests that these multiple rare mutations alone or combinations with each of prevalent mutations 
such as D442G and Int14+1A responsible for mild-to-moderate or marked HALP, respectively. 
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Figure legend 
Fig.1 The pedigree of subject 1  
The proband is indicated by an arrow. The father of proband had liver dysfunction and he died at 
his age of 75 of sudden death (I-1). The mother died at her age of 68 of cerebral infarction (I-2). 
The elder sister died of pneumonia after cerebral infarction at 83 years old (II-1), the second sister 
died of subarachnoid hemorrhage at 66 years old (II-2), and the younger sister died of renal failure 
at 52 years old (II-8). 
 
Fig.2 DNA sequences of exon 7 in CETP gene of normal allele.  
(A) and mutated allele (c.653_654delGGins AAAC) (B) from subject 1 by subclone sequencing. 
This mutation causes a frame shift leading to a premature stop codon in exon 8. The sequences (C) 
from subject 3 by direct sequencing revealed c.658 G>A heterozygote. 
 
Fig. 3 DNA sequences of exon 9 in CETP gene from control subject and subject 2. 
In subject 2, the direct sequence shows T to G substitution at codon 261 in exon 9, which means 
amino acid substitution from Leu (CTG) to Arg (CGG).  
 
Fig. 4 RT-PCR analysis of c.658G>A mutation transfected COS-1 cell  
(A) Schema of construct of CETP gene region in pCU 5-11 minigene vector is shown. (B) RT-
PCR analysis of CETP c.DNA region from a minigene construct transfected COS-1 cells. Mock 
plasmid, wild type and c.658 G>A mutant type pCU 5-11 minigene plasmid were transfected into 
COS-1 cells and total RNA was isolated and RT-PCR was performed by using CETP cDNA primer 
pair spanning from exon 2 to exon 9. (C) Sequencing analysis of RT-PCR product represents 628 
bp length product from c.658G>A transfected cell was skipping exon 7 and 558 bp product was 
skipping both exon 6 and 7. 
 
Fig. 5 Alignment of CETP amino acid sequences  
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Protein sequences of human, rabbit, chicken, xenopus and zebrafish are shown. The position of 
L261R is shown by an arrow. 
 
Fig. 6 Summary of CETP gene mutations   
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Ⅱ-4 Ⅱ-6(Subject 1) Ⅱ-7 Ⅲ-1 Ⅲ-3* Subject 2 Subject 3 Reference intervals
Age/Sex 74 M 65 F 75 M 44 F 38 M 50 F 72 F
BMI (kg/m²) 24.5 20.2 20.5 NA NA NA 16.4
Total cholesterol (mg/dL) 297 319 145 187 192 314 276 128–219
Triglyceride (mg/dL) 52 56 125 28 610 79 66 30–149
LDL-cholesterol (mg/dL)† 50 85 80 77 NA 151 101 57–139
HDL-cholesterol (mg/dL) 237 223 40 105 63 147 162 40–99
ApolipoproteinA-Ⅰ (mg/dL) 289 280 109 211 177 NA 275 122–161
ApolipoproteinA-Ⅱ (mg/dL) 58.5 32.6 23.3 26.3 38.9 NA NA 25.1–34.5
Apolipoprotein B  (mg/dL) 65 67 75 61 79 NA 76 69–105
Apolipoprotein C-Ⅱ (mg/dL) 6.8 5.2 5.2 2.2 4.3 NA NA 1.6–4.2
Apolipoprotein C-Ⅲ (mg/dL) 17.8 16.7 8.4 7.9 13.8 NA NA 5.5–9.5
Apolipoprotein E (mg/dL) 6.1 13.3 2.3 4.3 4.9 NA 3.8 2.7–4.5
CETP (μg/mL) <0.1 <0.1 1.2 1.4 1.0 <0.1 1.1 1.7–2.2
*: after meal, BMI: Body mass index, NA: not available, †: by Friedewald calculation
Table 1 Plasma lipids profile, CETP concentration and other parameters in subjects with CETP gene novel mutation and its family members
Table 2 CETP mass levels in medium of CETP wild type and L261R transfected COS-1 cells
Genotype CETP mass in medium（n=6)
Wild type 54.4±21.2 ng/mL
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Supplemental Fig. 1 
(A) CETP mass in conditioned media from COS-1 cells transiently transfected with 
wild-type, A203T and L261R mutant CETP cDNA expression vector  
Values are shown as mean and SEM (n=6). Statistical analysis was performed by 
ANOVA and Sheffé's test. The p-value by ANOVA was 0.01. p<0.05 by Sheffé's test 
was revealed as #. 
(B) RT-PCR analysis of CETP and GAPDH genes from wild-type, A203T and L261R 
CETP transfected COS-1 cells 




































Wild-type Wild-typeA203T A203TL261R L261R
CETP GAPDH
688bp
273bp
p=0.11
p=0.05
<0.25
